Autoimmune hemolytic anemia (AIHA) is a relatively uncommon disorder caused by autoantibodies directed against self red blood cells. It can be idiopathic or secondary, and classified as warm, cold (cold hemagglutinin disease (CAD) and paroxysmal cold hemoglobinuria) or mixed, according to the thermal range of the autoantibody. AIHA may develop gradually, or have a fulminant onset with life-thre...

Unlike other autoimmune polyneuropathies, the linkage between chronic inflammatory demyelinating polyneuropathy (CIDP) and other immune mediated disorders is weak. We report a patient who developed monophasic and parallel courses of autoimmune hemolytic anemia (AIHA) and chronic demyelinating polyneuropathy. Both resolved in tandem with corticosteroid therapy. Distinct from Guillain-Barre Syndr...

La presente investigación realizó un estudio sobre exposición a dosis de ruido trabajadores en una empresa fabricación y comercialización envases vidrio hidrolítico tipo 1. El objetivo fue caracterizar los perfiles GES por comparación resultados con el LMP. población del está conformada todos expuestos ruido, es 103 la muestra 45, metodología usada peor condición (Associates in Acoustics, 2009)...

BACKGROUND Many patients with autoimmune hemolytic anemia (AIHA) do not respond to standard therapy and/or may develop severe complications which can be of fatal outcome. There is some evidence that erythropoiesis-stimulating agents (ESAs) may be helpful in the management of such patients. METHODS We describe the effect of ESAs in 12 new patients with therapy-refractory AIHA (7 of warm type a...

The hallmark of the autoimmune hemolytic anemias (AIHAs) and paroxysmal nocturnal hemoglobinuria (PNH) is shortened red blood cell survival. Although AIHA and PNH share the critical feature of shortened red cell survival, the mechanisms underlying this characteristic differ significantly between the two diseases. In the case of AIHA, autoantibodies directed against the patient’s own red blood c...

BACKGROUND Autoimmune neutropenia (AIN) can occur in association with autoimmune hemolytic anemia (AIHA) and/or immune thrombocytopenic purpura (ITP), although these associations have not been studied in detail. METHODS AND RESULTS Twenty cases of AIN were found in a group of 55 adults with unexplained neutropenia over a five-year period. Eight subjects with AIN had an associated AIHA and/or ...

Hodgkin's lymphoma accounts for ten percent of all lymphomas. In the United States, there are about 8000 new cases every year. This paper describes a case of lymphocyte-rich Hodgkin's lymphoma (LRHL) manifested by autoimmune hemolytic anemia (AIHA). A 27-year-old Israeli male presented with dizziness associated with one month of low-grade fevers and night sweats; he also complained of persisten...

Graves' disease (GD) is associated with various hematologic abnormalities but pancytopenia and autoimmune hemolytic anemia (AIHA) are reported very rarely. Herein, we report a patient with GD who had both of these rare complications at different time intervals, along with a review of the related literature. The patient was a 70-year-old man who, during a hospitalization, was also noted to have ...

Standard treatment for autoimmune hemolytic anemia (AIHA) due to warm antibodies includes combinations of glucocorticoids, immunosuppressive drugs (mainly azathioprine) and splenectomy. Patients who are refractory or intolerant to these therapies constitute an important therapeutic challenge. Rituximab, an anti-CD20 chimeric monoclonal antibody, can effectively deplete B-cells and is commonly u...

Adalimumab is commonly used to treat autoimmune diseases with few reported hematological adverse reactions. We herein describe the case of an 85-year-old Japanese man with plaque psoriasis who developed autoimmune hemolytic anemia (AIHA) after 3 years of adalimumab treatment. The patient suddenly developed hematuria and dyspnea on exertion while receiving adalimumab treatment. Laboratory data s...